Associated tags: Oncology, Clinical Trials, Health, Biotechnology, Pharmaceutical, Pharmaceutical industry, Research, Patient, Other Health, Vaccine, STC, Science, Immune system, Education, Colorectal cancer, CSO, Cancer, Stem Cells
Locations: CANADA, FRANCE, EUROPE, USA, BALTIMORE, UNITED STATES, NORTH AMERICA, CALIFORNIA, BD, PARIS
Research,
Clinical Trials,
Biometrics,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Cancer,
Doctor,
MSI-H,
Metastasis,
Communication,
Immunotherapy,
Colorectal cancer,
Patient,
MSI,
STC,
Team,
Doctor of Philosophy,
Master of Science,
MSS,
Neoplasm,
Vaccine This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
Key Points:
- This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
- Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
- STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors.
- Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured.
Other Health,
Research,
General Health,
Oncology,
Medical Devices,
Infectious Diseases,
Genetics,
Clinical Trials,
Science,
Biotechnology,
Stem Cells,
Health,
Partner (business rank),
France Biotech,
Patient,
Cancer,
LEEM,
Imagination,
Creativity,
Merck Group,
IQVIA,
Multimedia,
Pharma,
Pharmaceutical industry Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
Key Points:
- Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
- The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
- (France Biotech Press Release)
This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before.
- Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients."
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
Neoplasm,
Patient,
Pharma,
State,
Education minister,
Human,
Reproduction,
Safety,
Acceleration,
SME,
Bioproduction,
ATMP,
Proteomics,
Immune system,
Pharmaceutical industry Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the " Innovations in Biotherapy and Bioproduction" call for proposals from France 2030 .
Key Points:
- Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the " Innovations in Biotherapy and Bioproduction" call for proposals from France 2030 .
- Brenus Pharma has developed the anti-cancer vaccine STC-1010, targeting metastatic colorectal cancer (mCRC), second leading cause of cancer mortality worldwide.
- "Brenus Pharma stands out for its innovative platform that generates new cellular and vaccine immunotherapies guided by proteomics.
- We thank the State via France 2030 for this support, which validates Brenus' technological approach and should accelerate its availability to patients," said Paul BRAVETTI , CEO of Brenus Pharma.
Retrieved on:
Thursday, December 14, 2023
Other Health,
Research,
Pharmaceutical,
Oncology,
Biometrics,
Other Education,
Education,
Clinical Trials,
Science,
Biotechnology,
Other Science,
Health,
Ecosystem,
Next Generation EU,
Heart,
PSCC,
Pharmaceutical industry Brenus Pharma has successfully joined the Paris Saclay Cancer Cluster (PSCC) , the first national Onco-cluster.
Key Points:
- Brenus Pharma has successfully joined the Paris Saclay Cancer Cluster (PSCC) , the first national Onco-cluster.
- This membership positions Brenus at the heart of the European initiative to accelerate and valorize innovation in oncology.
- Located in Grand Paris, PSCC brings together a diverse community of 80 members from 9 different nationalities.
- Focused on transforming the treatment of solid tumor cancers, Brenus Pharma stands out with its patented platform of anticancer vaccine immunotherapies.
Retrieved on:
Thursday, September 28, 2023
Oncology,
Health,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Mouse,
Clinical trial,
Entrepreneurship,
OVO,
Pharming,
STC,
Vaccine Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models.
Key Points:
- Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models.
- All our efforts are now focused on regulatory approvals and batch production for the clinical trial in 2024."
Pharmaceutical,
Health,
Oncology,
Clinical Trials,
CSO,
Education,
Personalized medicine,
Organizational founder,
INSERM,
Research,
Doctor of Philosophy,
Precision,
STC,
Patient,
Sidney Kimmel Comprehensive Cancer Center,
Colorectal cancer,
Immune system,
NL,
Dijon,
Immunology,
Society,
Vaccine,
Nursing Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
Key Points:
- Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
- This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
- The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
Pr François GHIRINGHELLI MD, PhD.
- Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Doctor,
CRC,
T cell,
Pharming,
Safety,
DC,
CAM,
Cancer,
Toxicity,
Doctor of Philosophy,
STC,
TCR,
Dendritic cell,
Patient,
Stimulated,
Colorectal cancer,
Master of Science,
Immune system,
Cross-presentation,
Neoplasm,
Team,
Pharmaceutical industry,
Vaccine,
Antibiotics,
Management Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.
Key Points:
- Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.
- These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.
- The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay.
- Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models.
Medical Devices,
Infectious Diseases,
Hospitals,
Clinical Trials,
Biometrics,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Partnership,
Education,
CSO,
ITD,
Cancer,
STC,
Synthase,
EMA,
Pharmacist,
Patient,
European,
Nursing,
Colorectal cancer,
Immune system,
ANSM,
Certification,
EFS,
MTI,
FDA,
Pharmaceutical industry,
Vaccine The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise.
Key Points:
- The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise.
- This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally.
- This public-private partnership aims for a long-term perspective and will lead in 2023 to the production of clinical batches for the Fist-In-Human study of STC-1010, Brenus Pharma's lead candidate, targeting colorectal cancer.
- We are 10,000 professionals, including doctors, nurses, biologists, technicians, pharmacists, collection teams, researchers, administrative staff… driven by the same vital mission.
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
LEEM,
CDMO,
Strategy,
Society,
Trust,
HEC Paris,
Doctor,
Immune system,
GE HealthCare,
MBA,
CSL Vifor,
Paris,
Non-executive director,
Patient,
CanSino Biologics,
STC,
Doctor of Pharmacy,
CSO,
Roche,
Education,
Fine chemical,
Management,
Pharmaceutical industry,
Vaccine,
Takeda BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.
Key Points:
- BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.
- Pierre MORGON (Pharm D, LL.M, MBA): CEO, MRGN Advisors ; Executive VP, CanSino Biologics; Board chairman and non-Executive director, several biotech.
- “We are delighted to have top renowned healthcare industry executives at our side to challenge and support our strategic plan and are thankful for their trust.
- Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.
